.svg){kind=small}
Discover opportunities months before the RFP drops
Learn more →Discover opportunities months before the RFP drops
Learn more →Key metrics and characteristics
The city where this buyer is located.
The county where this buyer is located.
Physical address of this buyer.
Postal code for this buyer's location.
How likely this buyer is to spend on new technology based on operating budget trends.
How likely this buyer is to adopt new AI technologies.
How often this buyer champions startups and early adoption.
Includes fiscal year calendars, procurement complexity scores, and strategic insights.
Active opportunities open for bidding
Office of Acquisitions Management
Seeking: First-in-class small molecule or peptide-based antifungals that are currently in Phase 2 clinical trials or beyond (e.g., including FDA or EMA approved) with an intended treatment and prophylaxis indications or treatment only indication to address drug-resistant invasive fungal infections (e.g., Candida spp., including Candida auris, and/or Aspergillus species). Broad-spectrum candidates that are effective against yeast and molds and that are available as oral and IV are desirable. See attached file.
Posted Date
May 21, 2026
Due Date
Jun 21, 2026
Release: May 21, 2026
Office of Acquisitions Management
Close: Jun 21, 2026
Seeking: First-in-class small molecule or peptide-based antifungals that are currently in Phase 2 clinical trials or beyond (e.g., including FDA or EMA approved) with an intended treatment and prophylaxis indications or treatment only indication to address drug-resistant invasive fungal infections (e.g., Candida spp., including Candida auris, and/or Aspergillus species). Broad-spectrum candidates that are effective against yeast and molds and that are available as oral and IV are desirable. See attached file.
AvailableOffice of Acquisitions Management
Abstracts on the following topics will be considered out of scope: Development of complete diagnostic devices or commercial test kits; Clinical validation studies or regulatory submission activities; Programs targeted toward vaccine or therapeutic antibody development; Nucleic acid-based binders (e.g., aptamers). See attached file.
Posted Date
Apr 15, 2026
Due Date
May 13, 2026
Release: Apr 15, 2026
Office of Acquisitions Management
Close: May 13, 2026
Abstracts on the following topics will be considered out of scope: Development of complete diagnostic devices or commercial test kits; Clinical validation studies or regulatory submission activities; Programs targeted toward vaccine or therapeutic antibody development; Nucleic acid-based binders (e.g., aptamers). See attached file.
Office of Acquisitions Management
The United States House of Representatives (Office of Acquisitions Management) issued Sources Sought OAM26027S seeking legal advisory services. The notice requests responses by April 30, 2026, at 2:00 p.m. EDT and falls under NAICS code 541110 for Offices of Lawyers. This solicitation is a sources-sought/RFI notice and is listed on both the House procurement opportunities page and SAM.gov.
Posted Date
Mar 31, 2026
Due Date
Apr 30, 2026
Release: Mar 31, 2026
Office of Acquisitions Management
Close: Apr 30, 2026
The United States House of Representatives (Office of Acquisitions Management) issued Sources Sought OAM26027S seeking legal advisory services. The notice requests responses by April 30, 2026, at 2:00 p.m. EDT and falls under NAICS code 541110 for Offices of Lawyers. This solicitation is a sources-sought/RFI notice and is listed on both the House procurement opportunities page and SAM.gov.
Get alerted before the bid drops, know which RFPs to pursue, and generate compliant drafts with AI.
Keep your public sector contacts fresh and actionable. No more stale data.
Premium
Win more deals with deep buyer insights
Premium
Access the largest public sector contact database
© 2026 Starbridge